Bone densitometry: Indications interpretation;Densitometría ósea: Indicaciones e interpretación

Endocrinologia y Nutricion

Volumn 52, Issue 5, 2005, Pages 224-227

  Munoz Torres M ^a,b   De La Higuera, M ^a   Fernandez Garcia D ^a   Alonso, G ^a   Reyes, R ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b NONE   (Spain)

Author keywords

Bone densitometry; Dual energy x ray absorptiometry; Osteoporo sis

Indexed keywords

BONE DENSITOMETRY; BONE DENSITY; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HUMAN; OSTEOPENIA; OSTEOPOROSIS; REVIEW; RISK FACTOR; TREATMENT INDICATION;

EID: 20544470972     PISSN: 15750922     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1575-0922(05)71019-6     Document Type: Review

References (18)

1. Muñoz-Torres M, Alonso G, Mezquita-Raya P. Prevención y tratamiento de la osteoporosis. Endocrinol Nutr. 2003;50:1-7.
2. Grupo de trabajo de la SEIOMM. Osteoporosis posmenopáusica. Guía de práctica clínica. Rev Cin Esp. 2003;203:496-506.
3. NIH Consensus Development. Panel on osteoporosis prevention, diagnosis and therapy. JAMA. 2001;285:785-95.
4. Kanis JA, Glüer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporosis Int. 2000;11:192-202.
5. Jacobsen SJ, Goldberg J, Miles TP, et al. Race and sex differences in mortality following fracture of the hip. Am J Public Health. 1992;82:1147-50.
6. Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporosis fractures in the United States in 1995: report from the National Osteoporosis Foundation. Bone Miner Res. 1997;12:24-35.
7. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;2018-26.
8. De la Higuera López-Frías M, Fernández Gracia D, Muñoz-Torres M. Densitometría ósea: usos clínicos y evidencia científica. Rev Clin esp. 2004;204:480-2.
9. Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, et al. Official Positions of the International Society for Bone and Mineral Research. J Clin Endocrinol Metab. 2004;89:3651-5.
10. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry. JAMA. 2002;288:1889-97.
11. Black DM, Palermo L, Bauer D. How well does bone mass predict long-term risk of the hip fracture? Osteoporosis Int. 2000;11 Suppl 2:S59.
12. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. JAMA. 2001;286:2815-22.
13. Kanis JA, Johnell O, Oden A, Sernbo I, Redlung-Johnell I, Dawson A, et al. Long-term risk of osteoporotic fractures in Malmö. Osteoporosis Int. 2000;11:669-74.
14. Johnell O, Oden A, De Laet C, Garnero P, Delmas PD, Kanis JA. Biochemical indices of bone turnover and the assessment of fracture. Osteoporosis Int. 2002;13:523-6.
15. AACC Osteoporosis Task Force. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis updates for 2003. Endocr Prac. 2003;9:545-64.
16. National Osteoporosis Foundation. Physician's Guide to prevention and treatment of Osteoporosis. Washington DC: National Osteoporosis Foundation; 2003.
17. Cummings SR, Nevitt MC, Browner WS. Risk factors for hip fracture inwhite women. Study of Osteoporotic Fracture Research Group. N Engl J Med. 1995;767-73.
18. US Preventive Services Task Force. Screening for Osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526-8.